Op bewijs gebaseerde artikelen over GLP-1-bijwerkingen, prijzen, generieke varianten en veiligheid.
Generic semaglutide is now launching in India, Canada, and Brazil. Is it the same as Ozempic? Here's what equivalence actually means — and what to look for.
Lees meerOzempic costs €300+ per month in some countries and €14 in others. Here's the patent economics behind the price — and why 2026 is changing everything.
Lees meerConsidering semaglutide for weight management? Here's what to expect in week 1, month 1, and beyond — from dose titration to side effects to lifestyle pairings.
Lees meerCounterfeit and grey market semaglutide is a growing problem. Here's how to tell if what you're buying is the real thing — and what to do if you're not sure.
Lees meerIndia's semaglutide patent expired March 20, 2026. Within 48 hours, 15 generic versions launched at ₹1,290/month — a 90% drop from Ozempic. Here's what it means for Indian patients.
Lees meerA clear, non-hype explanation of what semaglutide actually does inside your body — the gut, the brain, the pancreas — and why that matters for how you take it.
Lees meerThree brand names, two molecules, very different labels. Here's an honest comparison of Ozempic, Wegovy, and Mounjaro — what the differences actually mean for patients.
Lees meerNausea is the most common reason people stop semaglutide in the first month. Here's a practical, evidence-based playbook for getting through the first four weeks.
Lees meerGLP-1 drugs like semaglutide and tirzepatide are not for everyone. Here's an honest list of who should not take them, and why — from contraindications to caution cases.
Lees meerGLP-1 drugs do a lot, but diet still matters — maybe more than you think. Here's what to eat to protect muscle, avoid nausea, and get the most out of semaglutide.
Lees meerRetatrutide, een experimenteel triple-agonist afvalmedicijn, wordt gelinkt aan emotionele vervlakking en verminderde romantische gevoelens. Wat zegt de wetenschap?
Lees meerVan GLP-1 tot dual- en triple-agonisten: hoe werken deze moleculen in je lichaam? De scheikunde achter gewichtsbeheer, uitgelegd zonder jargon.
Lees meerEen eerlijk overzicht van de bijwerkingen, risico's en veiligheidsdata van gewichtsbeheermedicatie. Wat zegt de wetenschap? En hoe minimaliseer je risico's?
Lees meerJe gaat naar de diëtist maar het gewicht beweegt niet. Wanneer is het tijd voor medische ondersteuning naast voedingsadvies? En wat kost het in 2026?
Lees meerWeight Watchers, Noom of een ander dieetprogramma geprobeerd zonder resultaat? Ontdek waarom diëten alleen vaak niet genoeg is en welke medische alternatieven er zijn.
Lees meerMerkmedicatie voor gewichtsverlies kost €150-500/maand en wordt in 2026 meestal niet vergoed. Ontdek het alternatief via magistrale bereiding, prijs zelf af te spreken met je apotheek.
Lees meerMedisch afvallen hoeft niet duur te zijn. Vergelijk de kosten van alle opties in Nederland: van diëtist tot bereidingsapotheek. Ontdek het betaalbare alternatief.
Lees meerMagistrale bereiding is het op maat maken van medicatie door een apotheker. Ontdek hoe het werkt, waarom het legaal is, en wat de voordelen zijn ten opzichte van standaard merkproducten.
Lees meerOntdek waarom steeds meer Nederlanders kiezen voor gepersonaliseerde gewichtsbeheerprogramma's via bereidingsapotheken. Betaalbaar, effectief en onder medisch toezicht.
Lees meerVergelijk magistrale bereidingen met standaard merkproducten. Kosten, kwaliteit, dosering en veiligheid — alles op een rij voor Nederlandse consumenten.
Lees meerDit artikel beschreef een 4-stappen Magistra-dienst — vragenlijst, artsbeoordeling, apotheekmatching en bezorging. Die dienst bestaat niet. Wat een bereide behandeling in Nederland in het algemeen vereist, en wat Magistra wél publiceert: onafhankelijke GLP-1-data.
Lees meerHoe veilig zijn magistrale bereidingen? Een overzicht van de Nederlandse en Europese regelgeving, kwaliteitscontroles en registratie-eisen voor bereidingsapotheken.
Lees meerEen eerlijke vergelijking van de kosten van gewichtsbeheerprogramma's in Nederland. Van diëtisten tot merkproducten tot magistrale bereidingen — wat kost het echt?
Lees meerHoe vind je zelf een erkende bereidingsapotheek in Nederland, en waar moet je op letten — BIG-registratie, IGJ-inspectie en faciliteiten? Magistra biedt geen apotheekzoeker; wij publiceren onafhankelijke GLP-1-data.
Lees meerBereken je BMI en ontdek wanneer een gepersonaliseerd gewichtsbeheerprogramma zinvol is. Met uitleg over BMI-categorieën en wat je opties zijn in Nederland.
Lees meerMagistra bewaart geen persoonlijk gezondheidsdossier. Wat we wél opslaan (wachtlijst-e-mail, contactbericht), waar het staat (EU), en welke AVG-rechten je hebt.
Lees meerDieetpillen vs. magistrale bereiding: wat is het verschil? Waarom gepersonaliseerde programma's via een arts en apotheek veiliger en effectiever zijn.
Lees meerAn evidence-grounded look at the Chinese semaglutide and tirzepatide peptide trade — what an independent lab test can and cannot tell you about a vial, the legal reality country by country, and what patients should know before relying on this supply chain.
Lees meerAn evidence-grounded forecast of GLP-1 medication supply and demand through 2030. Manufacturing capacity, generic ramp, demand drivers (cardiovascular, kidney, sleep apnea, oral formulations), the role of insurance unlock, and what the 2031 OECD generic wave actually means for affordability.
Lees meerWhat happens when one country has $40/month generic semaglutide and another has $1,349/month branded — until 2031? An evidence-grounded look at the legal arbitrage now opening up: who travels to India, what gets through customs, the difference between the Indian-generic gray market and the Chinese-peptide gray market, and how the trade likely evolves.
Lees meerIn January 2026 the GPhC tightened the rules on how UK pharmacies can supply Wegovy, Mounjaro and other weight-loss jabs. Online questionnaire-only prescribing is no longer permitted; pharmacies must conduct a two-way consultation and independently verify BMI. Here's what changed, why, and what it means for patients seeking treatment and doctors providing it.
Lees meerWe audited every UK company with 'peptide' in its name on Companies House. 98 are brand new with no track record, none of the credible ones supply GLP-1, and one woman has already died. Here's what patients need to know — and the safe alternative.
Lees meerWe track 15 GLP-1 side effects in our real-world evidence database. After a 31 August 2026 correction excluded seed rows from the eligible base, only 1 currently clears our bar for a fully calibrated statistical model. Here's exactly which one, why, and what's published instead for the other 14.
Lees meer14 of the 15 GLP-1 side effects we track have a published rate pooled directly from our own corpus of clinical trial and regulatory sources — not copied from a single paper. Here is every number, with its confidence interval, exactly how many sources it rests on, and the corrections that shaped the eligible base.
Lees meerOf the distinct community reports we hold from people on GLP-1 medications — Reddit threads and Drugs.com patient reviews — which side effects come up most? All 15 reporting frequencies with their denominator, what this number deliberately is not (an incidence rate), why we count mentions instead of averaging what posts claim, and the 2026-08-29 correction that cut the pool from 185 reports to 26.
Lees meerThe US label warns that gallstone risk goes up. A meta-analysis of 76 randomized trials agrees — especially at weight-loss doses. A 32,052-patient cohort study published in December 2025 found the opposite direction in one high-risk population. Here is every number, the population it belongs to, and what our own evidence base holds.
Lees meerPersonalised risk tools give you one number. It is really two ingredients multiplied together — an evidenced base rate and a set of profile multipliers — and almost nobody shows you the second. Here are all 75 of ours, including the fact that none of them carries a citation.
Lees meerThe US semaglutide label puts hair loss at 3% versus 1% on placebo, and says it was associated with weight reduction and reported several times more often in women than in men. The tirzepatide registry posts alopecia per arm at about 5% versus 1.1%, and as of 7 September 2026 those three arms are also our own database's first eligible clinical rates for the effect — here is every number, the arm and n it belongs to.
Lees meerSearch "how common is vomiting on Ozempic" and every answer gives you one number with no source. Our own corpus held 15 distinct sources that state a vomiting rate on 10 September 2026 — fourteen trials and one review quoting a fifteenth — and they range from 6.5% (an 8,803-patient cardiovascular outcome trial) to 58% (a 6-person early-phase pharmacology study). Both are real. Here is every trial, its population, its n, and why the range is this wide rather than a defect in the data.
Lees meerThe US semaglutide label puts constipation at 24% on Wegovy 2.4 mg against 11% on placebo, so nearly half the headline is the background rate. We read the placebo arm of every constipation source in our corpus that posts one — from an 8,803-patient cardiovascular trial to a 61-participant dose-ranging study — and in the weight-reduction trials the label itself pools, the drug-minus-placebo difference is 11 to 14 points every time. Here is every arm, its n, and why our own pooled 11.8% is not the Wegovy number.
Lees meerBekijk uw persoonlijke GLP-1 bijwerkingsrisico